A Study in Reversing Hepatic Fibrosis or Cirrhosis Related to Hepatitis B Virus and Finding Biomarkers

• Status: Unknown status
• Trial end date: 2021-09-30
• Target enrollment: 0
• Participant gender: All

Summary

The aim of our study is to validate the non-invasive model which was constructed by our previous study for evaluating liver fibrosis or cirrhosis caused by hepatitis B virus in mainland China and to find a therapeutic regimen to reverse liver fibrosis and cirrhosis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking University First Hospital
• Treatments: Entecavir

Criteria

Inclusion Criteria:

1. HBsAg positive for at least 6 months

2. Agree to have liver biopsy

3. Male or female aged 18 to 70 years old -

Exclusion Criteria:

1. Patients with alcoholic liver disease, autoimmune liver disease, heretic liver disease, drug induced liver disease, nonalcoholic liver disease or other chronic liver disease

2. Platelet count < 80 × 10^9/L

3. Prothrombin activity ≤ 60%

4. Decompensated liver cirrhosis

5. Patients with any disease or condition which the investigator or treating physician feels would interfere with the trial or the safety of the subject -